Fudan University

🇨🇳China

Country: 🇨🇳China

Ownership: Private

Established: 1905-01-01

Employees: 1K

Market Cap: -

Website: http://www.fudan.edu.cn

Clinical Trials

Camrelizumab Combined With Bevacizumab and HAIC in Patients With Metastatic Liver Cancer Who Failed Standard Therapy

Phase 1

Not yet recruiting

Conditions: Metastatic Liver Cancer

Interventions: Drug: HAIC、Bevacizumab、Camrelizumab

First Posted Date: 2022-12-08

Last Posted Date: 2022-12-08

Lead Sponsor: Fudan University

Target Recruit Count: 80

Registration Number: NCT05643417

Locations: 🇨🇳
Fudan University Shanghai Cancer Center, Shanghai, Shanghai, China

Low Dose Decitabine in Combination With Tirelizumab Comparison of Tirelizumab in the First-line Treatment of Advanced Esophageal Squamous Cell Carcinoma

Phase 2

Not yet recruiting

Conditions: PFS

Interventions: Drug: tirelizumab
Drug: Decitabine Injection

First Posted Date: 2022-12-06

Last Posted Date: 2022-12-06

Lead Sponsor: Fudan University

Target Recruit Count: 60

Registration Number: NCT05638984

Evaluation of a Model for the Early Diagnosis of Colorectal Cancer by the Detection of 5-hydroxymethylcytosine (5-hmC) in Plasma Cell-free DNA to the Community Colorectal Cancer Screening Program

Recruiting

Conditions: Colorectal Neoplasms
Colorectal Cancer

First Posted Date: 2022-12-06

Last Posted Date: 2022-12-06

Lead Sponsor: Fudan University

Target Recruit Count: 10000

Registration Number: NCT05638243

Locations: 🇨🇳
Community Health Centers in Xuhui District, Shanghai, Shanghai, China

The Efficacy and Safety of Fruquintinib Plus FOLFIRI/FOLFOX as Second-line Treatment in Patients With RAS-mutant Metastatic Colorectal Cancer

Phase 2

Not yet recruiting

Conditions: Metastatic Colorectal Cancer

Interventions: Drug: Fruquintinib
Drug: FOLFIRI
Drug: mFOLFOX6

First Posted Date: 2022-12-02

Last Posted Date: 2022-12-02

Lead Sponsor: Fudan University

Target Recruit Count: 68

Registration Number: NCT05634590

Locations: 🇨🇳
Department of Colorectal Surgery Fudan University Shanghai Caner Center, Shanghai, Shanghai, China

Predictive Value of ctDNA for NED Status in mCRC and Its Utility in Guiding Therapeutic Intervention

Not Applicable

Recruiting

Conditions: No Evidence of Disease Status
ctDNA Monitoring
Metastatic Colorectal Cancer

Interventions: Other: ctDNA
Other: ctDNA and adjuvant therapy

First Posted Date: 2022-12-02

Last Posted Date: 2022-12-02

Lead Sponsor: Fudan University

Target Recruit Count: 110

Registration Number: NCT05635630

Locations: 🇨🇳
Fudan University Shanghai Cancer Center, Shanghai, Shanghai, China

Peripheral Blood Neoantigen Specific T Cells Predict the Efficacy of Immunotherapy for Esophageal Squamous Cell Carcinoma

Recruiting

Conditions: Esophageal Squamous Cell Carcinoma

First Posted Date: 2022-12-01

Last Posted Date: 2022-12-02

Lead Sponsor: Fudan University

Target Recruit Count: 60

Registration Number: NCT05633641

Locations: 🇨🇳
Cancer hospital Fudan University, Shanghai, Shanghai, China

Modulation Therapy for Locally Advanced NPC Based on Plasma EBV DNA Level Post-ICT

Phase 2

Recruiting

Conditions: Nasopharyngeal Cancer

Interventions: Other: Induction chemotherapy and concurrent chemoradiation
Drug: Toripalimab

First Posted Date: 2022-11-29

Last Posted Date: 2022-11-29

Lead Sponsor: Fudan University

Target Recruit Count: 198

Registration Number: NCT05628922

Locations: 🇨🇳
Fudan Universtiy Shanghai Cancer Centre, Shanghai, Shanghai, China

The Combination of Hypofractionated Radiotherapy and Immunotherapy in Locally Recurrent Rectal Cancer

Phase 2

Recruiting

Conditions: Recurrent Rectal Cancer

Interventions: Drug: PD-1 antibody
Drug: Capecitabine
Drug: 5FU
Drug: folinic acid
Drug: Oxaliplatin
Drug: Irinotecan
Drug: Raltitrexed
Drug: Cetuximab
Drug: Bevacizumab
Radiation: Radiation

First Posted Date: 2022-11-28

Last Posted Date: 2024-10-01

Lead Sponsor: Fudan University

Target Recruit Count: 93

Registration Number: NCT05628038

Locations: 🇨🇳
Fudan University Shanghai Cancer Center, Shanghai, Shanghai, China

Assessment of Prognosis Using Peripheral Blood Circulating Tumor DNA in Patients With Cervical Cancer

Recruiting

Conditions: Locally Advanced Cervical Cancer

Interventions: Other: detect HPV and genetic variants

First Posted Date: 2022-11-02

Last Posted Date: 2022-11-02

Lead Sponsor: Fudan University

Target Recruit Count: 108

Registration Number: NCT05602831

Locations: 🇨🇳
Fudan University Shanghai Cancer Center, Shanghai, China

SNF Platform Study of HR+/ HER2-advanced Breast Cancer

Phase 2

Recruiting

Conditions: HER2-negative Breast Cancer
Advanced Breast Cancer
Breast Neoplasm
Breast Cancer
Hormone Receptor Positive Tumor

Interventions: Drug: PIK3CA inhibitor
Drug: AKT inhibitor
Drug: SHR-A1811
Drug: Carrelizumab
Drug: SHR-1167
Drug: Famitinib
Drug: Sorafenib
Drug: Everolimus
Drug: Fluzoparib
Drug: Aromatase Inhibitors or Fulvestrant
Drug: TPC
Drug: SHR-A1921
Drug: SHR-6209
Drug: Dalpiciclib
Drug: Apatinib
Drug: SHR-A2009
Drug: SHR-A2102
Drug: Goserelin
Drug: bevacizumab

First Posted Date: 2022-10-26

Last Posted Date: 2024-10-04

Lead Sponsor: Fudan University

Target Recruit Count: 620

Registration Number: NCT05594095

Locations: 🇨🇳
Breast cancer institute of Fudan University Cancer Hospital, Shanghai, Shanghai, China

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy